arGEN-X Receives Two Preclinical Milestone Payments Under Collaboration With Shire

January 13, 2014

BREDA, The Netherlands and GHENT, Belgium, January 13, 2014 /PRNewswire/ –

Enters into pilot research agreement with Boehringer Ingelheim

arGEN-X, a clinical stage human therapeutic antibody company, announces the attainment
of two important success milestones in its SIMPLE Antibody(TM) research and product
development collaboration with Shire. The milestones, which trigger undisclosed payments
from Shire, relate to demonstration of in vivo proof of concept for one of the ongoing
antibody discovery programs.

Initiated in February 2012, the collaboration is focused on creating human therapeutic
antibodies against complex targets implicated in severe, rare genetic diseases. Shire has
an option to license the most promising antibody leads for further development and
commercialization worldwide, in return for fee, milestone and royalty payments.

“Yet again the functional diversity of SIMPLE Antibodies(TM) has enabled our
scientists to set a precedent in validating highly complex targets both in vitro and in
vivo and identifying antibody leads with exciting therapeutic potential,” said Hans de
Haard, PhD, Chief Scientific Officer of arGEN-X. “We value our collaboration with Shire
very highly and continue to make excellent progress through the outstanding joint efforts
of our teams.”

“We are very impressed by the productivity and consistent success of our therapeutic
antibody collaboration with arGEN-X,” said Albert Seymour, Head of Discovery Biology and
Translational Research at Shire.

arGEN-X today also announced the initiation of a new pilot research agreement with
Boehringer Ingelheim. No further details are being disclosed at this stage.

About arGEN-X

arGEN-X is a clinical stage human therapeutic antibody company that is rapidly
developing a product pipeline using its unique suite of antibody technologies. arGEN-X is
creating first and best in class antibody therapeutics with highly differentiated target
product profiles. Its therapeutic antibody programs, focused on cancer and autoimmune
indications, are designed to deliver tangible benefits to patients with these diseases.



Source: PR Newswire

comments powered by Disqus